These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35675800)

  • 1. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
    Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
    Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.
    Desjardins EM; Wu J; Lavoie DCT; Ahmadi E; Townsend LK; Morrow MR; Wang D; Tsakiridis EE; Batchuluun B; Fayyazi R; Kwiecien JM; Tsakiridis T; Lally JSV; Paré G; Pinkosky SL; Steinberg GR
    Cell Rep Med; 2023 Sep; 4(9):101193. PubMed ID: 37729871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 6. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
    Burke AC; Huff MW
    Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
    PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
    Feng X; Zhang L; Xu S; Shen AZ
    Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
    Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
    J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice.
    Yenilmez B; Kelly M; Zhang GF; Wetoska N; Ilkayeva OR; Min K; Rowland L; DiMarzio C; He W; Raymond N; Lifshitz L; Pan M; Han X; Xie J; Friedline RH; Kim JK; Gao G; Herman MA; Newgard CB; Czech MP
    J Biol Chem; 2022 Oct; 298(10):102401. PubMed ID: 35988648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score.
    Sanjay KV; Vishwakarma S; Zope BR; Mane VS; Mohire S; Dhakshinamoorthy S
    Curr Res Pharmacol Drug Discov; 2021; 2():100051. PubMed ID: 34909677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
    Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
    Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
    Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
    J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
    Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
    Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mendelian Randomization Study of
    Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
    N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Steatotic Cells, ATP-Citrate Lyase mRNA Is Efficiently Translated through a Cap-Independent Mechanism, Contributing to the Stimulation of De Novo Lipogenesis.
    Siculella L; Giannotti L; Testini M; Gnoni GV; Damiano F
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.